Targeting Mnks for Cancer Therapy

Jinqiang Hou; Frankie Kam; Christopher G Proud; Shudong Wang

doi:10.18632/oncotarget.453

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Targeting Mnks for Cancer Therapy

Jinqiang Hou, Frankie Kam, Christopher G Proud and Shudong Wang _

PDF | HTML | How to cite

Oncotarget. 2012; 3:118-131. https://doi.org/10.18632/oncotarget.453

Metrics: PDF 5488 views | HTML 6729 views | ?

Abstract

Jinqiang Hou¹, Frankie Lam¹, Christopher Proud² and Shudong Wang¹

¹ School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

² Centre for Biological Sciences, University of Southampton, Southampton, UK

Received: February 16, 2012; Accepted: February 29, 2012; Published: March 3, 2012;

Keywords: eIF4E, Mnk, Ras, Raf, MAPK, Akt, PI3K, mTOR, Targeted Cancer Therapy, Structure based drug design, Mnk Inhibitors

Correspondence:

Shudong Wang,

Abstract

Deregulation of protein synthesis is a common event in human cancer and a key player in translational control is eIF4E. Elevated expression levels of eIF4E promote cancer development and progression. Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer. The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK. While the phosphorylation event is necessary for oncogenic transformation, it seems to be dispensable for normal development. Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective anti-cancer strategy. Strong circumstantial evidence indicates that Mnk inhibition presents attractive therapeutic potential, but the lack of selective Mnk inhibitors has so far confounded pharmacological target validation and clinical development.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 453

Publication Alerts

Reviews:

Targeting Mnks for Cancer Therapy

Abstract